Therapeutic inhibitors targeting these checkpoints, such as anti-PD-1 antibodies and anti-CTLA-4 antibodies, are applied in treating ccRCC and other malignancies, and have shown tremendous clinical benefits (73). This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.